Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz

Clinical Snapshot

Key Findings

• P Value: P < 0.05 for all primary comparisons

• Effect Size: Higher CD3+ and CD4+ levels in nevirapine group, lower CD8+ levels

• Primary Outcome: CD4+ T lymphocyte count improvement favouring nevirapine group

• Nnt Or Sensitivity: Not calculable from available data

• Confidence Interval: CD3+: 45.2-98.7, CD4+: 32.8-76.4

Clinical Application

Both regimens are established first-line options, though efavirenz increasingly replaced by integrase inhibitors Limited relevance as current Australian HIV guidelines favour integrase inhibitor-based regimens over NNRTI-based therapy as first-line treatment Treatment-naive HIV patients suitable for first-line antiretroviral therapy

Abstract

This study aimed to explore the efficacy of lamivudine + zidovudine plus nevirapine and efavirenz in the treatment hf human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS). A total of 100 patients with HIV/AIDS admitted to our hospital from June 2021 to September 2024 were selected and randomly assigned into nevirapine and efavirenz groups (n = 50 per group). The nevirapine group was treated with lamidudine plus zidovudine combined with nevirapine, and the efavirenz group was treated with lamidudine plus zidovudine plus efavirenz. The primary outcomes measured were the changes of lymphocyte count and adverse effects after 3 months of treatment. There was no statistical difference in baseline information between the 2 groups. After treatment, CD3 + and CD4 + levels were higher in the nevirapine group than in the efavirenz group (P <.05, 95% CI: 45.2-98.7 for CD3 + and 32.8-76.4 for CD4+), and CD8 + levels were lower in the nevirapine group than in the efavirenz group (P <.05); the overall incidence of adverse effects in the nevavirapine group was significantly lower than that in the efavirenz group (P <.05). In HIV/AIDS patients, treatment with lamivudine + zidovudine combined with nevirapine resulted in significantly improved CD4 + T cell counts, enhanced immune function, and fewer adverse reactions compared to treatment with lamivudine + zidovudine plus efavirenz, suggesting superior clinical value of the nevirapine-containing regimen.

References

1. 1.Zhu, X., & Zou, M. (2026). Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz. Medicine, Article 0000000000048049. https://doi.org/10.1097/MD.0000000000048049